AR038619A1 - Derivados de 2-piridinil y 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona substituidos por heteroarilo - Google Patents
Derivados de 2-piridinil y 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona substituidos por heteroariloInfo
- Publication number
- AR038619A1 AR038619A1 ARP030100657A ARP030100657A AR038619A1 AR 038619 A1 AR038619 A1 AR 038619A1 AR P030100657 A ARP030100657 A AR P030100657A AR P030100657 A ARP030100657 A AR P030100657A AR 038619 A1 AR038619 A1 AR 038619A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- ring
- alkyl group
- equal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pest Control & Pesticides (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
Abstract
Un medicamento que comprende dicho derivado ó una sal del mismo como ingrediente activo, que se utiliza para el tratamiento preventivo y/o terapéutico de una enfermedad neurodegenerativa causada por la actividad anormal de la GSK3beta o de la GSK3beta y la cdk5/p25, como ser enfermedad de Alzheimer. Reivindicación 1:Un derivado de pirimidona representado por la fórmula (1) ó una sal del mismo, ó un solvato del mismo ó un hidrato del mismo, caracterizado porque: X representa dos átomos de hidrógeno, un átomo de azufre, un átomo de oxígeno ó un grupo alquilo C1-2 y un átomo de hidrógeno; Y representa un enlace, un grupo etenileno, un grupo etinileno ó un grupo metileno opcionalmente sustituido por uno o dos grupos seleccionados entre un grupo alquilo C1-6, un grupo hidroxi ó un grupo alcoxi C1-4; R1 representa un anillo de 2, 3 ó 4-piridina ó un anillo de 2, 4 ó 5-pirimidina, y el anillo está opcionalmente sustituido por un grupo cicloalquilo C3-6, un grupo alquilo C1-4, un grupo alcoxi C1-4, un grupo bencilo ó un átomo de halógeno; R2 representa anillos bicíclicos heterocíclicos, que tienen entre 1 y 4 heteroátomos seleccionados entre un átomo de oxígeno, un átomo de azufre y un átomo de nitrógeno, y que tienen C5-9, de fórmula (2) donde A, B, C y D representan, cada uno independientemente, un átomo de carbono ó un átomo de nitrógeno, y W representa un anillo cíclico de 5, 6 ó 7 miembros saturado o insaturado, que tiene C3-7 y entre 2 y 0 heteroátomos tales como un átomo de oxígeno, un átomo de azufre ó un átomo de nitrógeno; el grupo R2 está opcionalmente sustituido en un átomo de carbono ó, cuando fuere posible, en un átomo de nitrógeno por uno ó dos átomos ó grupo seleccionados entre un átomo de halógeno, un grupo alquilo C1-6, un grupo hidroxi, un grupo alcoxi C1-4, un anillo de benceno, un anillo de piridina ó un grupo -NR6R7; R3 representa un átomo de hidrógeno, un grupo alquilo C1-6, un grupo hidroxi, un grupo alcoxi C1-4 ó un átomo de halógeno; R4 representa un átomo de hidrógeno, un grupo alquilo C1-6, un grupo alcoxi C1-4 ó un átomo de halógeno; R5 representa un átomo de hidrógeno, un grupo alquilo C1-6, un grupo alquilo perhalogenado C1-2, un grupo alquilo halogenado C1-3 ó un átomo de halógeno; R6 y R7 representan, cada uno independientemente un átomo de hidrógeno, un grupo alquilo C1-6, un grupo bencilo, un anillo de benceno, ó R6 y R7 representan conjuntamente con el átomo de nitrógeno, un anillo de pirrolidina, un anillo de piperidina, un anillo de hexametilenimina, un anillo de morfolina ó un anillo de piperazina, y el anillo está opcionalmente sustituido por 1 ó 2 grupos alquilo C1-6; cuando m es igual a 0, p es igual a 1, 2 ó 3; cuando m es igual a 1, p es igual a 0, 1 ó 2; cuando m es igual a 2, p es igual a 0 ó 1; cuando m es igual a 3, p es igual a 0; y n representa entre 0 y 3; con la condición de que el derivado de fórmula (1) no sea: 9-[2-(1H-indol-3-il)etil]-2-piridin-4-il-6,7,8,9-tetrahidro-4H-pirimido[1,2-a]pirimidin-4-ona; 9-[3-(1H-indol-3-il)propil]-2-piridin-4-il-6,7,8,9-tetrahidro-4H-pirimido[1,2-a]pirimidin-4-ona; 1-[2-(1H-indol-3-il)etil]-7-piridin-4-il-2,3-dihidroimidazo[1,2-a]pirimidin-5(1H)-ona; ó 1-[3-(1H-indol-3-il)propil]-7-piridin-4-il-2,3-dihidroimidazo[1,2-a]pirimidin-5(1H)-ona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02290485A EP1340758A1 (en) | 2002-02-28 | 2002-02-28 | Heteroaryl substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
| EP02290486A EP1348708A1 (en) | 2002-02-28 | 2002-02-28 | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038619A1 true AR038619A1 (es) | 2005-01-19 |
Family
ID=27767034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100657A AR038619A1 (es) | 2002-02-28 | 2003-02-28 | Derivados de 2-piridinil y 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona substituidos por heteroarilo |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7232827B2 (es) |
| EP (1) | EP1480983B1 (es) |
| JP (1) | JP4458851B2 (es) |
| KR (1) | KR101030629B1 (es) |
| CN (1) | CN1315832C (es) |
| AR (1) | AR038619A1 (es) |
| AT (1) | ATE309247T1 (es) |
| AU (1) | AU2003221500B9 (es) |
| BR (1) | BR0308109A (es) |
| CA (1) | CA2474823C (es) |
| DE (1) | DE60302221T2 (es) |
| DK (1) | DK1480983T3 (es) |
| EA (1) | EA007737B1 (es) |
| ES (1) | ES2250883T3 (es) |
| IL (1) | IL163287A (es) |
| MX (1) | MXPA04008364A (es) |
| NO (1) | NO329805B1 (es) |
| NZ (1) | NZ534466A (es) |
| PL (1) | PL372465A1 (es) |
| SI (1) | SI1480983T1 (es) |
| TW (1) | TWI303637B (es) |
| WO (1) | WO2003072579A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542136A (en) | 2003-03-07 | 2008-07-31 | Sanofi Aventis | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| EP1454910A1 (en) | 2003-03-07 | 2004-09-08 | Sanofi-Synthelabo | Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
| EP1723427A2 (en) * | 2004-02-26 | 2006-11-22 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b) |
| DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| DE102004010194A1 (de) * | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| FR2947551B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| FR2947550B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| PL2448939T3 (pl) * | 2009-07-02 | 2017-08-31 | Sanofi | Pochodne 2,3-dihydro-1h-imidazo {1,2-a} pirymidyn-5-onu, ich wytwarzanie i ich zastosowanie farmaceutyczne |
| MX2012000103A (es) * | 2009-07-02 | 2012-05-22 | Sanofi Sa | Nuevos derivados de 1,2,3,4-tetrahidro-pirimido (1,2-a) pirimidin-6-ona, su preparacion y su uso farmaceutica. |
| CN102715186A (zh) * | 2012-06-15 | 2012-10-10 | 王学权 | 一种增效除草组合物 |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| ES2759277T3 (es) * | 2014-04-01 | 2020-05-08 | Pfizer | Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopiracinadionionas como moduladores de gamma-secretasa |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| JP6967302B2 (ja) * | 2017-05-24 | 2021-11-17 | アビスコ セラピューティクス カンパニー リミテッド | アザアリール誘導体、その製造方法および薬学上の応用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| AU2002212249B9 (en) | 2000-09-01 | 2007-01-18 | Mitsubishi Pharma Corporation | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
-
2003
- 2003-02-26 KR KR1020047013466A patent/KR101030629B1/ko not_active IP Right Cessation
- 2003-02-26 US US10/504,677 patent/US7232827B2/en not_active Expired - Fee Related
- 2003-02-26 CA CA2474823A patent/CA2474823C/en not_active Expired - Fee Related
- 2003-02-26 CN CNB038092549A patent/CN1315832C/zh not_active Expired - Fee Related
- 2003-02-26 WO PCT/EP2003/002651 patent/WO2003072579A1/en active IP Right Grant
- 2003-02-26 SI SI200330138T patent/SI1480983T1/sl unknown
- 2003-02-26 DE DE60302221T patent/DE60302221T2/de not_active Expired - Lifetime
- 2003-02-26 ES ES03717210T patent/ES2250883T3/es not_active Expired - Lifetime
- 2003-02-26 PL PL03372465A patent/PL372465A1/xx not_active IP Right Cessation
- 2003-02-26 AT AT03717210T patent/ATE309247T1/de active
- 2003-02-26 JP JP2003571285A patent/JP4458851B2/ja not_active Expired - Fee Related
- 2003-02-26 NZ NZ534466A patent/NZ534466A/en not_active IP Right Cessation
- 2003-02-26 BR BR0308109-5A patent/BR0308109A/pt active Search and Examination
- 2003-02-26 EP EP03717210A patent/EP1480983B1/en not_active Expired - Lifetime
- 2003-02-26 MX MXPA04008364A patent/MXPA04008364A/es active IP Right Grant
- 2003-02-26 DK DK03717210T patent/DK1480983T3/da active
- 2003-02-26 EA EA200400936A patent/EA007737B1/ru not_active IP Right Cessation
- 2003-02-26 AU AU2003221500A patent/AU2003221500B9/en not_active Ceased
- 2003-02-27 TW TW092104217A patent/TWI303637B/zh not_active IP Right Cessation
- 2003-02-28 AR ARP030100657A patent/AR038619A1/es unknown
-
2004
- 2004-07-29 IL IL163287A patent/IL163287A/en not_active IP Right Cessation
- 2004-08-26 NO NO20043565A patent/NO329805B1/no not_active IP Right Cessation
-
2007
- 2007-05-16 US US11/749,349 patent/US7465737B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038619A1 (es) | Derivados de 2-piridinil y 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona substituidos por heteroarilo | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| WO2015121812A1 (en) | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| RU2368608C2 (ru) | Производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 | |
| AR049696A1 (es) | Derivados de indol | |
| AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
| AR039567A1 (es) | Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa, composicion farmaceutica y procedimiento de preparacion del compuesto | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| AR051686A1 (es) | Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4. | |
| AR025735A1 (es) | Compuestos terapeuticos | |
| ES2696708T3 (es) | Uso de derivados de bencimidazol-prolina | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR087710A1 (es) | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para su uso | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| AR048001A1 (es) | Hidroxi - 6 - fenilantridinas que contienen tio con actividad inhibitoria de pde4 y composiciones farmaceuticas que las contienen para el tratamiento de trastornos respiratorios. | |
| AR069691A1 (es) | Derivados ciclopropilamina | |
| ES2902521T3 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de ALK-2 | |
| BRPI0408189A (pt) | 8'-piridinil-dihidroespiro-[cicloalquil]-pirimido[1,2-a]p irimidin-6-ona substituìda e derivados de 8'-pirimidinil-dihidroespiro-[cicloalquil]-pirimido[1,2- a]pirimidin-6-ona e seus usos contra doenças neurodegenerativas | |
| AR036600A1 (es) | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido [1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h) ona sustituidos | |
| AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| NO20072046L (no) | Halogensubstituerte benzodiazepinderivater | |
| AR050711A1 (es) | Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |